Status of vaccine research and development of vaccines for tuberculosis

Highlights • Tuberculosis is now the leading infectious disease cause of death in the world. • There are more than 10 clinical candidates in various phases of clinical development. • The preclinical portfolio remains small as compare to the problem, and needs novel immunologic approaches. • A correl...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2016-06, Vol.34 (26), p.2911-2914
Main Authors: Evans, Thomas G, Schrager, Lew, Thole, Jelle
Format: Article
Language:English
Subjects:
Adenoviruses
Allergy and Immunology
Animal models
Animals
Antibiotic resistance
Antigens
BCG
BCG Vaccine - therapeutic use
Biomedical Research - trends
Candidates
Clinical trials
Clinical Trials as Topic
Disease transmission
Drug resistance
Funding
Global health
Humans
Immune system
Infections
Influenza
Latency
Mass Vaccination
Mortality
Mycobacterium
Mycobacterium tuberculosis
Portfolio management
Prevention
Proteins
Public health
R&D
Research & development
Teenagers
Tuberculosis
Tuberculosis - prevention & control
Tuberculosis Vaccines - therapeutic use
Vaccine
Vaccines
Young adults
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • Tuberculosis is now the leading infectious disease cause of death in the world. • There are more than 10 clinical candidates in various phases of clinical development. • The preclinical portfolio remains small as compare to the problem, and needs novel immunologic approaches. • A correlate of vaccine-induced protection is not known. • Mass vaccination of adolescents and young adults will likely be the most effective strategy.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2016.02.079